
    
      This is a 9-month, multicenter open-label safety extension study. Subjects who have
      successfully completed Study IPX203-B16-02 [A Randomized Controlled Study to Compare the
      Safety and Efficacy of IPX203 with Immediate-Release (IR) Carbidopa-Levodopa (CD-LD) in
      Parkinson's Disease Patients with Motor Fluctuations] may have the opportunity to enroll in
      this open-label study.
    
  